K
Kyung-Jo Kim
Researcher at University of Ulsan
Publications - 170
Citations - 5222
Kyung-Jo Kim is an academic researcher from University of Ulsan. The author has contributed to research in topics: Crohn's disease & Inflammatory bowel disease. The author has an hindex of 34, co-authored 170 publications receiving 4334 citations. Previous affiliations of Kyung-Jo Kim include Inje University & Asan Medical Center.
Papers
More filters
Journal ArticleDOI
Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study.
Suk-Kyun Yang,Sung-Cheol Yun,Jin-Ho Kim,Joon Yong Park,Hak Yang Kim,Young Ho Kim,Dong Kyung Chang,Joo Sung Kim,In Sung Song,Jong Beom Park,Eui-Ryun Park,Kyung-Jo Kim,Gyoo Moon,Soo Hyun Yang +13 more
TL;DR: The incidence and prevalence of Crohn's disease and ulcerative colitis in Seoul, Korea are still low compared with those in Western countries, but are rapidly increasing.
Journal ArticleDOI
A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia
Suk-Kyun Yang,Myunghee Hong,Jiwon Baek,Hyunchul Choi,Wanting Zhao,Yusun Jung,Talin Haritunians,Byong Duk Ye,Kyung-Jo Kim,Sang Hyoung Park,Soo-Kyung Park,Dong-Hoon Yang,Marla Dubinsky,Inchul Lee,Dermot P.B. McGovern,Jianjun Liu,Kyuyoung Song +16 more
TL;DR: A nonsynonymous SNP in NUDT15 (encoding p.Arg139Cys) that was strongly associated with thiopurine-induced early leukopenia in subjects with inflammatory bowel disease of European descent is identified and is a pharmacogenetic determinant for thiopURine- induced leuk Openia in diverse populations.
Journal ArticleDOI
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G. Feagan,William J. Sandborn,Geert R. D'Haens,Julián Panés,Arthur Kaser,Marc Ferrante,Edouard Louis,Denis Franchimont,Olivier Dewit,Ursula Seidler,Kyung-Jo Kim,Markus F. Neurath,Stefan Schreiber,Paul Scholl,Chandrasena Pamulapati,Bojan Lalovic,Sudha Visvanathan,Steven J. Padula,Ivona Herichova,Adina Soaita,David B. Hall,Wulf O. Böcher +21 more
TL;DR: In this short-term study, risankizumab was more effective than placebo for inducing clinical remission in patients with active Crohn's disease and selective blockade of interleukin-23 via inhibition of p19 might be a viable therapeutic approach in Crohn’s disease.
Journal ArticleDOI
Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations
Suk-Kyun Yang,Myunghee Hong,Wanting Zhao,Yusun Jung,Jiwon Baek,Naeimeh Tayebi,Kyung Mo Kim,Byong Duk Ye,Kyung-Jo Kim,Sang Hyoung Park,Inchul Lee,Eunju Lee,Won Ho Kim,Jae Hee Cheon,Young Ho Kim,Byung Ik Jang,Hyun Soo Kim,Jai Hyun Choi,Ja Seol Koo,Ji Hyun Lee,Sung Ae Jung,Yeoun Joo Lee,Joo Young Jang,Hyoung Doo Shin,Daehee Kang,Hee Shang Youn,Jianjun Liu,Kyuyoung Song +27 more
TL;DR: This study provides new biological insight to Crohn's disease and supports the complementary value of genetic studies in different populations.
Journal ArticleDOI
Endoscopic submucosal dissection for treatment of rectal carcinoid tumors
Hye Won Park,Jeong Sik Byeon,Young Su Park,Dong-Hoon Yang,Soon Man Yoon,Kyung-Jo Kim,Byong Duk Ye,Seung-Jae Myung,Suk-Kyun Yang,Jin-Ho Kim +9 more
TL;DR: Compared with EMR, ESD resulted in a higher histologically complete resection rate, had a similar complication rate, and took slightly longer to perform, indicating that ESD may be considered for treatment of rectal carcinoid tumors.